A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.
Stocks ended 2024 near record highs. Earnings growth accelerated. The market rally finally began to broaden. And despite a brief growth scare that spooked investors in late summer, the US economy ...